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 Highlights 
 
 Track potential behavioural changes throughout a patients’ epilepsy treatment. 
 Consider qualities of the chosen AED; seek a reduced behavioural adverse effect. 
 A behavioural modification plan should be trialled in the first instance. 
 For anxiety, consider starting fluoxetine at 0.125-0.167mg/kg/day. 
 Treatment of behavioural comorbidities may not effect seizure control and vice versa. 
 
 
 
Abstract 
 Psychiatric comorbidities affect a large percentage of people with epilepsy and have a 
detrimental impact on their quality of life.  Recently, behavioural comorbidities, with similar 
characteristics to human psychiatric diseases, have been identified in dogs with idiopathic 
epilepsy.  In particular, behaviours motivated by the fear-anxiety emotional system have been 
found to be associated with the occurrence of idiopathic epilepsy in both dogs receiving anti-
epileptic drugs, and drug-naïve dogs.  There has been little research into the relationship 
between epilepsy and behavioural signs, and even less into potential treatment protocols.  The 
following article will review available literature from human medicine to describe the current 
state of knowledge about the bi-directional relationship between anxiety and epilepsy, draw 
parallels from reported anxiogenic and anxiolytic properties of anti-epileptic drugs and attempt 
to provide pharmaceutical and behavioural guidance for veterinary patients with epilepsy and 
comorbid anxiety. 
 
Keywords: Idiopathic epilepsy; Psychiatric comorbidity; Canine behaviour; Anxiety; Dog 
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Introduction 
The existence of comorbid psychiatric disorders with epilepsy is long-established in 
human medicine and prevalence is much higher for epilepsy than other chronic medical 
conditions or healthy controls (Davies et al., 2003).  The most common psychiatric 
comorbidities for epilepsy patients include depression, cognitive dysfunction and anxiety 
disorder with reported prevalence rates of 36.5% (Ettinger et al., 2015), 26.4% (Berg et al., 
2008) and 22.8% (Tellez‐Zenteno et al., 2007), respectively.  Of course, prevalence alone does 
not make psychiatric comorbidities important, and the effect on a patient’s quality of life (QoL) 
should also be taken into account (Brandt and Mula, 2016).  
 
In the veterinary world, idiopathic epilepsy (IE) is a common neurological condition 
(Heske et al., 2014; Kearsley-Fleet et al., 2013). Some breeds show high disease prevalence or 
increased odds of having IE such as Belgian Shepherds, Border Terriers, Labradors and 
German Shepherd Dogs (Berendt et al., 2015; Hülsmeyer et al., 2015; Kearsley-Fleet et al., 
2013).  Despite epilepsy being a common brain disease in dogs, few studies to date have 
investigated the presence of neurobehavioural comorbidities in canine epilepsy. Shihab et al. 
(2011) and Jokinen et al. (2015) have reported behavioural changes in dogs following onset of 
IE and similarities to the comorbidities experienced by people.  The recent consensus 
statements published by the International Veterinary Epilepsy Task Force (IVETF) agree that 
neurobehavioural changes should be monitored in future treatment trials (Potschka et al., 
2015).  As voiced by Packer and Volk (2015), QoL for epileptic dogs is of paramount 
importance, especially to owners (Chang et al., 2006; Packer et al., 2016), and psychiatric 
comorbidities will contribute to this.  This article will address anxiety disorder comorbid with 
epilepsy (ADCE), will focus on the evidence reported in people and draw parallels to veterinary 
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medicine to raise awareness of this behavioural comorbidity in dogs and how it may be 
improved to promote canine QoL. 
 
Anxiety disorder comorbid to epilepsy in people 
Anxiety can be a normal, transient mental (emotional) state in specific situations, but 
abnormal anxiety, which is not justified by the context or results in behavioural responses 
which are out of proportion in intensity or duration can occur2. Anxiety disorder can be related 
to concurrent physical health issues and this would lead to a separate diagnosis from other 
anxiety disorders (American Psychiatric Association, 2015). In people with epilepsy, comorbid 
anxiety disorders can manifest in a multitude of ways (Beyenburg et al., 2005) and occur twice 
as often in people with epilepsy than those without (Tellez‐Zenteno et al., 2007). Comorbid 
anxiety disorders can have a negative impact on health-related QoL, which has been found to 
be more significant than both seizure chronicity and severity (Johnson et al., 2004). 
Considering their high prevalence, these anxiety disorders are chronically under-diagnosed and 
under-treated in people (Kimiskidis and Valeta, 2012; Thomé-Souza et al., 2007). Under-
diagnosis of anxiety disorders in veterinary patients has been extensively described (Overall et 
al., 2016). Misinterpretation of normal and pathological anxiety (Tami and Gallagher, 2009) 
and lack of recognition of mild clinical signs by owners (Mariti et al., 2012) are likely to 
contribute to the under reporting of comorbid anxiety disorders in veterinary species.  
 
What links anxiety disorders and epilepsy? 
It is thought that shared anatomy and physiology through the amygdala, hippocampus 
and neuronal pathways such as the serotonin, glutamate and gamma-aminobutyric acid 
pathways explain why epilepsy and anxiety disorders are linked, and support a bi-directional 
                                                 
2 American Psychiatric Association, 2017. What are anxiety disorders? 
https://www.psychiatry.org/patients-families/anxiety-disorders/what-are-anxiety-disorders 
(accessed 29 July 2017). 
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relationship (Loss et al., 2012; Brandt and Mula, 2016; Kwon and Park, 2014; Mula, 2013).  
Evidence of a bi-directional relationship has been shown in genetic rat models of epilepsy; not 
only were those rats more anxious than controls, but anxiety began before the onset of epilepsy, 
which disregards psychosomatic, psychosocial and neurodegenerative causes for anxiety 
following onset of epilepsy (Jones et al., 2008).  The existence of a bi-directional relationship 
is corroborated by two human studies where a significantly increased incidence rate ratio of 
anxiety disorders was found two years before and three years after initial epilepsy diagnosis 
compared to controls (Hesdorffer et al., 2012) and increased odds of seizure development was 
found pre- and post-anxiety diagnosis (Adelöw et al., 2012).  
 
Anxiety disorders as a comorbidity in dogs 
Anxiety disorders are common in veterinary species, regularly leading to behavioural 
responses which are reported as being problematic (Dreschel, 2010).  Unfortunately, as Roshier 
and McBride (2013) explains, there is poor and incomplete recognition of animal behaviour 
within the veterinary profession, and, whilst research documenting specific psychological 
disorders in dogs is evident (Cannas et al., 2010; Palestrini et al., 2010), little in known in 
relation to epileptic patients. Shihab et al. (2011) found significantly increased anxiety in dogs 
following IE onset, assessed using the Canine Behavioural Assessment and Research 
Questionnaire.  Fear and anxiety levels were increased in both drug-naïve and those receiving 
various antiepileptic drugs (AEDs), suggesting that anxiety could either be an adverse effect 
of AEDs alone, or a combination of both adverse effect and comorbidity.  De Risio et al., 
(2015) reported behavioural changes such as anxiety in Italian Spinone’s, following onset of 
IE but prior to commencing AED therapy.  The effect of anxiety disorders on the health-related 
QoL of dogs should not be underestimated; chronic anxiety disorders can have a significant 
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impact, causing chronic fatigue, contributing to a range of physical health concerns and other 
behaviours (Bowen and Heath, 2005). 
 
Anxiogenic/Anxiolytic effects of AEDs 
Anxiogenic and anxiolytic effects of AEDs are well described in human medicine.  
Unfortunately, studies are small with high variability in method and population and, conflicting 
results are common due to lack of blinded and randomized studies. Veterinary research 
currently only addresses owner-reported increases in anxiety as an adverse effect, making the 
true anxiolytic effect of AEDs in dogs challenging to conclude.  Owner-reported adverse 
effects have limitations including likelihood of subjectivity and poor owner perception of 
anxiety.  
 
In human medicine, phenobarbital and potassium bromide have fallen out of favour, 
and so little evidence of psychiatric merit or disadvantage exists.  Phenobarbital has a complex 
mechanism of action (Mula et al., 2007) and, despite historical use as an anxiolytic (Yasiry and 
Shorvon, 2012), its use has been largely superseded by newer generations of medication and 
it’s lack of anxiolytic properties has become apparent.   Primidone, which is rapidly 
metabolized to phenobarbital (Podell et al., 2016), is thought to increase the likelihood of 
anxiety disorders in epileptic patients; Lopez-Gomez and Espinola (2008) found that use of 
primidone predicted anxiety disorders in a cross-sectional study of 196 patients with epilepsy, 
though it was impossible to separate this from other predictive factors and analyse the effect of 
AEDs in this study.  Levetiracetam could be considered anxiolytic due its mild GABAergic 
action (Landmark, 2008; Muralidharan and Bhagwagar, 2006) and evidence from rat models 
(Gower et al., 2003).  Hagemann et al. (2013) found that add-on and monotherapy 
levetiracetam decreased seizure frequency and improved QoL, anxiety and depression scores 
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in 65 of 140 patients. However, a systematic review by Cramer et al. (2003) found that epilepsy 
patients treated with levetiracetam, were more likely to show affective anxiety symptoms than 
those taking a placebo, but rates were lower than rates reported for other AEDs used in people 
where sufficient data exists such as lamotrigine, vigabatrin and zonisamide. 
 
Pregabalin has been investigated more than other AEDs for anxiolytic potential and is 
licensed in treatment for generalised anxiety disorder in people (Brandt et al., 2013; Mula et 
al., 2007).  Although not licensed as a treatment for ADCE (Brandt and Mula, 2016), Mula 
(2013) has suggested that it should be considered the first-line AED in such patients.  Brandt 
et al. (2013) found that pregabalin reduced seizure frequency and significantly reduced anxiety 
scores in people with ADCE.  Gabapentin is also considered an effective anxiolytic as it 
enhances GABAergic neurotransmission (Kwon and Park, 2014; Landmark, 2008; Weintraub 
et al., 2007) and has shown no significant anxiogenesis between control or treated adults as an 
add-on AED (Harden et al., 1999).  Zonisamide is largely anxiolytic and has been shown to 
significantly decrease anxiety in historically non-responsive adults with epilepsy (Kinrys et al., 
2007) and in newly-diagnosed children with epilepsy (Eun et al., 2011).  However, a 3% 
increase in anxiety was seen in treated patients compared to controls in a double-blinded add-
on trial (Cramer et al., 2003).   
 
 Topiramate has a complex mechanism of action (Howard et al., 2011; Perucca and 
Mula, 2013). In the literature, Mula and Trimble (2003) reported that 2.55% of epileptic 
patients treated with topiramate developed anxiety disorders, though overall adverse effect rate 
was higher (35.90%). Similarly, Marson et al. (2007) reported a 3.97% incidence of anxiety as 
an adverse effect in 378 patients receiving topiramate, amongst an overall adverse effect 
incidence of >50%. Felbamate is thought to be an anxiogenic (Ketter et al., 1996; Kimiskidis 
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and Valeta, 2012; Kwon and Park, 2014) due to its antiglutamatergic action (Beyenburg et al., 
2005; Vazquez and Devinsky, 2003).  A small, randomized, placebo controlled study by 
Theodore et al. (1995) found that six of 13 patients receiving felbamate monotherapy dropped 
out due to intolerable adverse effects including anxiety disorder.  
 
In veterinary medicine, a systematic review and meta-analysis (Charalambous et al., 
2016) found no reports of increased anxiety in dogs receiving phenobarbital, potassium 
bromide, levetiracetam, zonisamide and felbamate, though the evidence was considered weak 
for the latter.  The authors reported that anxiety was an adverse effect of primidone, reported 
in just under 10% of studies (Charalambous et al., 2016).  There was not enough evidence into 
the efficacy of pregabalin, gabapentin or topiramate as AEDs to assess safety profile or adverse 
effects, additionally there is insufficient evidence to suggest that pregabalin works as an 
effective AED in veterinary patients (Bhatti et al., 2015).  A consensus statement by The 
American College of Veterinary Internal Medicine (ACVIM) (Podell et al., 2016) listed hyper-
excitability and restlessness as predictable and dose-dependent adverse effects of phenobarbital 
treatment; both behaviours could be interpreted by owners as a clinical sign of anxiety or have 
other causes (Bowen and Heath, 2005).  Podell et al. (2016) concurred with Charalambous et 
al. (2016) in reporting no anxiety-related adverse effects in dogs taking potassium bromide 
alone or in addition to phenobarbital.  Unfortunately, both the systematic review and consensus 
statement referenced here are subject to ascertainment bias. Many of the adverse effects 
reported have not been purposefully screened for, it is unknown whom they were identified by 
and what diagnostic criteria or tool was used to come upon the report of “anxiety”. 
Additionally, carefully agreed and accurate terminology is desperately needed for canine 
anxiety diagnosis, especially in instances of comorbidity (Overall, 2005). This is particularly 
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important in comorbid disorders, where occurrence of clinical signs can be separate from signs 
of the comorbid disorder, or altered by it (Overall et al., 2001).  
 
Imepitoin is licensed solely for dogs, first being developed for humans due to its good 
anticonvulsant and anti-anxiety properties in rodent models (Rundfeldt and Löscher, 2014).  
The ACVIM consensus statement reported no anxiety as an adverse effect of imepitoin (Podell 
et al., 2016), however, Charalambous et al. (2016) states that around 10% of studies reported 
dose-dependent and reversible anxiety when receiving imepitoin.  Rundfeldt et al. (2015) found 
central nervous system effects were among the most common in dogs treated with low 
(1mg/kg) and high-dose (30mg/kg) imepitoin, shown in 52% and 72% of dogs, respectively.  
Rundfeldt et al. (2015) reported significantly increased adverse effects and adverse reactions 
in the high-dose group.  Central nervous system adverse effects were not individually specified 
but included ataxia, restlessness, hyperactivity and disorientation.  Packer et al. (2017) found 
no change in fear and anxiety-related behavioural scores in 85 dogs before or during treatment 
for IE with imepitoin, but this could be due to the retrospective nature of the study design or 
be caused by differences in effect of the drug upon the epileptic brain and the ‘normal’ brain, 
particularly for drug-resistant dogs.  The use of imepitoin in canine behavioural medicine for 
the management of sound related fears has been reported (McPeake and Mills, 2017).  
Anecdotally, there is one report of imepitoin used to treat anxiety in a cat (Dube, 2015).  
 
In veterinary medicine polypharmacy is common in attempts at seizure control, let 
alone in the considerations of other problems such as anxiety.  Research into the likelihood of 
polypharmacy-induced anxiogenesis in people is mixed; Ettinger et al. (1998) and IJff et al. 
(2015) found no significant difference in anxiety or increased adverse effects in polypharmacy 
patients compared to monotherapy human patients.  However, others (Adewuya and Ola, 2005; 
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Oguz et al., 2002; Williams et al., 2003) found that polypharmacy was a significant risk factor 
associated with increased anxiety disorder in children and adolescent patients.  Whilst the link 
between increased anxiety disorders and polypharmacy remains questionable we must also 
consider the possibility that a patient with a more drug-resistant phenotype might have other 
abnormalities in the brain which predispose them to more anxiety than drug-responsive 
phenotypes. Alternatively, multiple medications might not be the direct cause of increased 
levels of anxiety, but that having a more intractable epilepsy phenotype necessitating 
polypharmacy, might make a patient more likely to have detrimental levels of anxiety (Ekinci 
et al., 2009).   
 
It is important to remember that, for dogs, only phenobarbital and imepitoin are licensed 
for first-line treatment in the European Union; all other drugs are either only licensed as add-
on adjunctive therapies or unlicensed so only approved for use following failure of approved 
drugs, those include; levetiracetam, zonisamide, felbemate, topiramate, gabapentin and 
pregabalin (Bhatti et al., 2015). 
 
Pharmacological treatment of anxiety in epileptic patients 
In 2011, the International League Against Epilepsy (ILAE) produced consensus 
statements to set out unequivocal guidelines on the treatment of neuropsychiatric conditions 
associated with epilepsy in people (Kerr et al., 2011).  The ILAE consider selective serotonin 
reuptake inhibitors (SSRIs) to be the first-line drug for the treatment of anxiety disorders, and 
indeed depression, in people with epilepsy due to their low adverse effect profile and their lack 
of effect on seizure threshold.  Beyenburg et al. (2005) found SSRIs to carry a 0.1% risk of 
seizures so they are considered ‘low risk’.  A Cochrane Library systematic review (Maguire et 
al., 2015) concluded that the evidence for use of any antidepressant in the presence of epilepsy 
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was low but that the few studies available indicated that SSRIs do not significantly increase 
seizure frequency.  Thomé-Souza et al. (2007) followed 36 children and adolescents with 
epilepsy and depression for at least three months prior to and until one year after starting 
fluoxetine or sertraline treatment.  Two children had increased seizure frequency, one of which 
was resolved by adjusting the AED and the other withdrew from the study. Both SSRIs were 
found to be effective for the comorbid depression, with few adverse effects.  A similar study 
(Kanner et al., 2000) found that in 100 adult patients with epilepsy and depression prescribed 
sertraline, only six had an increase in seizure frequency, which was controlled by AED dosage 
adjustments in five patients.  Fifty-four percent of participants’ depression responded to the 
SSRI, which the authors explained is in line with the general population without epilepsy. Most 
research into efficacy of SSRIs and effect on seizure frequency in people with epilepsy are in 
relation to depression, rather than anxiety. In a population of people with epilepsy and 
comorbid depression and/or anxiety disorder, Ribot et al. (2017) has shown has reported a 
clinical response to SSRIs (reduction in depression and/or anxiety) in more than 70% of their 
patient cohort and SSRIs did not seem to affect their seizure frequency, actually reducing it by 
>50% in 48% of patients. 
 
Interestingly, two literature reviews (Cardamone et al., 2013; Igelström and Heyward, 
2012) found that the majority of research into the effect of SSRIs on seizure frequency on 
animal models of epilepsy found them to be either anticonvulsant or to exert no effect at all on 
seizure frequency.  In rat and mouse models of epilepsy, fluoxetine and its active metabolite 
norfluoxetine have been shown to reduce seizure frequency or reduce seizure threshold when 
compared to positive and negative controls, in stressed and non-stressed conditions (Hernandez 
et al., 2002; Kecskeméti et al., 2005; Peričić et al., 2005; Richman and Heinrichs, 2007).  
Similar research into SSRI usage to treat dogs with ADCE is lacking, however, it can be 
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assumed that they are safe and only anxiolytic efficacy must be proven in future.  SSRIs have 
been used in healthy dogs with anxiety problems in combination with behaviour modification 
plans with good effect (Simpson et al., 2007; Ibáñez and Anzola, 2009; Karagiannis et al., 
2015; Pineda et al., 2014), which can also be said of clomipramine (King et al., 2000; Crowell-
Davis et al., 2003). 
 
The ILAE also deemed serotonin and norepinephrine reuptake inhibitors, 
benzodiazepines, azapirones, antihistamines and pregabalin safe for treatment of people with 
ADCE (Kwon and Park, 2014).  Despite anecdotal, off-license use of fluoxetine in veterinary 
epilepsy patients with anxious behaviour, it should be noted that the ILAE consensus statement 
advises against fluoxetine and fluvoxamine due to possible cytochrome inhibition, which 
affects the pharmacokinetics of drug metabolism, particularly of phenobarbital, phenytoin and 
St. John’s Wort (Bhatti et al., 2015; Hemeryck and Belpaire, 2002; Kerr et al., 2011; Zanger 
and Schwab, 2013), leading them to recommend sertraline as a safer substitute. There are a 
number of references in behavioural medicine text books on sertraline’s use in dogs with 
anxiety (Bowen and Heath, 2005; Horwitz and Mills, 2010; Overall, 2013). 
 
One veterinary study has looked at the owner-perceived effect of the AED imepitoin 
on anxiety in dogs with IE but reported no difference between pre- and post-treatment levels 
(Packer et al., 2017).  Regardless of the negative results, this study contributes an important 
starting point towards the development of potential treatments for dogs with ADCE.  Dogs are 
considered a naturally-occurring model of human epilepsy and so pharmacokinetics and 
neuronal pathways could, believably, be quite similar (Berendt et al., 2004; Chandler, 2006; 
Licht et al., 2002), allowing application of human research and medication recommendations 
within the confines of prescribing laws.  Assuming, based on ILAE guidelines as mentioned 
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above, that SSRIs should be the first choice in dogs with ADCE to treat the anxiety disorder 
alongside their chosen AEDs, then fluoxetine should be considered first. Frustratingly, given 
the evidence described here, it is currently contraindicated in animals with a history of seizures 
(BSAVA, 2014), though this is not consistent worldwide and some merely advise caution 
(Plumb, 2008).  Additional options for the safe treatment of dogs with ADCE; selegiline, a 
monoamine oxidase inhibitor, and clomipramine hydrochloride, a tricyclic antidepressant 
(TCA) are both suboptimal choices, as will be explained.   
 
In human medicine, TCAs have been shown to have a significantly higher risk of 
seizures than SSRIs; 1% for clomipramine compared to 0.1% for SSRIs (Ekinci et al., 2009; 
Kanner, 2016), but evidence of this in animals receiving therapeutic doses is unestablished 
(Petersen et al., 1985).  In veterinary medicine in the UK, clomipramine is licensed for use in 
dogs with separation-related behaviours with proven efficacy (King et al., 2000; Landsberg, 
2001; Overall and Dunham, 2002; Seksel and Lindeman, 2001).  Despite this, no research 
exists that investigates the effect of clomipramine on dogs with ADCE, though prescribing 
instructions note that care is warranted in epileptic dogs as plasma levels of some AEDs such 
as phenytoin and carbamazepine may be increased (BSAVA, 2014; Landsberg, 2001).  
Selegiline is licensed to treat emotional behavioural disorders in dogs in Europe (BSAVA, 
2014) because it has been suggested to reduce anxiety in some cases, although there is limited 
evidence for efficacy. However, there are caveats about using this medication in households 
with a history of inter-dog tension, due to the potential effect of increased confidence on the 
relationship between them (Bowen and Heath, 2005).  Some authors have suggested caution in 
households where there is a history of aggression, which could be of concern in epileptic dogs 
that display aggressive behaviour during the post-ictal stage.  Shihab et al. (2011) has shown 
that drug naïve dogs with IE have increased aggression compared to before the onset of disease, 
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so risk-taking with drugs that could potentially elevate this behaviour should be avoided.  Many 
benzodiazepines can be used off-license in dogs with anxiety disorders and are generally not 
contraindicated for use in dogs with seizures or epilepsy and, of course, some of these drugs 
are used to halt seizure activity in an emergency situation (BSAVA, 2014).  However, long-
term treatment with these drugs is contraindicated due to their interference with memory and 
learning; additionally, there are suggestions in the veterinary literature that benzodiazepines 
can cause disinhibition, where a dog could become more likely to respond aggressively to a 
situation (BSAVA, 2014). However, this is not consistent with some reports in the human 
psychiatric literature for example a retrospective review of a heterogeneous population of 323 
psychiatric inpatients (Rothschild et al., 2000) suggested that disinhibition associated with 
benzodiazepine use may not be an clinically relevant problem. Extrapolation of information 
from human literature should always be considered with caution but this does highlight the 
need for more research into the potential behavioural side effects of medications in non-human 
animals. 
 
Given that the necessary drugs are currently described as contraindicated for epilepsy, 
prescription of any drug would be ‘off data-sheet’.  An SSRI should be trialled initially. In 
epileptic patients, human medicine recommends a dose 6-8 times smaller than the usual starting 
dose that is titrated up to effect (Kwon and Park, 2014), but there are no such recommendations 
for dogs. There is more evidence for efficacy of fluoxetine for treatment of anxiety disorder in 
dogs (Ibáñez and Anzola, 2009; Landsberg et al., 2008) and therefore, despite the 
contraindications this should be the first drug of choice. Based on the guidelines described 
above, fluoxetine can be started at 0.125-0.167mg/kg/day in dogs with ADCE, based on the 
dosing recommendation of 1-2mg/kg/day in BSAVA (2014). Efficacy of SSRIs may not 
become apparent for 3-6 weeks following commencement of treatment (Brandt and Mula, 
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2016); in human medicine doses are reviewed every 3-4 weeks and changed as necessary3.    
Between psychoactive drugs of different class (e.g. SSRI to TCA), gradual dose reduction and 
a drug-free period of at least a week, sometimes longer, is recommended to avoid withdrawal 
or rebound phenomena (Cerovecki et al., 2013).   If the dog is affected by separation anxiety, 
in particular, then a clinician might consider starting with clomipramine in the same manner, 
whilst being cautious of the possibility for increasing seizure activity and monitoring 
pharmacointeractions. Local drug prescribing laws and regulations will need to be considered. 
 
As reported in human medicine papers described above, it may be that alterations to 
AED doses are required should seizure activity increase with any of these medications. It may 
be that having IE causes the brain to respond differently to a drug when compared to a dog 
without a global brain disorder and, therefore, whilst a drug has anxiolytic properties these may 
not apply to a dog with ADCE. 
 
Alternative treatment of anxiety in epileptic patients 
Ketogenic diets are recommended for people with drug-resistant epilepsy and they have 
been shown to reduce seizure frequency (Neal et al., 2008).  Ketogenic diets come in many 
forms, classically in a 4:1 or 3:1 ratio of fat to minimal protein and carbohydrate (Neal et al., 
2008). A modified version uses mainly medium-chain triglycerides as a fat source as they yield 
more ketones and are absorbed and metabolised more efficiently (Lambrechts et al., 2017; Neal 
et al., 2009) whilst allowing safer levels of protein and carbohydrate to be eaten (Neal et al., 
2009).  The aim of a ketogenic diet is to induce a metabolic response similar to that seen after 
                                                 
3 NICE, 2017. British National Formulary: Fluoxetine 
https://www.evidence.nhs.uk/formulary/bnf/current/4-central-nervous-system/43-
antidepressant-drugs/433-selective-serotonin-re-uptake-inhibitors/fluoxetine (accessed 15 
February 2017) 
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starvation, which causes the brain to use ketone bodies, ß-hydroxybutyrate and acetoacetate, 
as its primary energy source due to an inadequate supply of glucose (Neal et al., 2009). 
However, the full neurological benefit and mechanism remains unknown; studies in people 
have reported reduction in ADHD-like behaviour (Pulsifer et al., 2001) and the offspring of 
rats fed a ketogenic diet whilst pregnant have been found to be less susceptible to anxiety and 
depression postnatally, compared to controls (Sussman et al., 2015).  A Cochrane Review 
(Levy et al., 2012) concluded that a ketogenic diet could improve seizure control but was 
generally intolerable, though evidence levels were low and largely in children.  Veterinary 
trials with ketogenic or medium-chain triglyceride diets have largely focused on their potential 
to reduce seizure frequency, and have had mixed results (Law et al., 2015; Pan et al., 2010; 
Patterson et al., 2005).  A randomized, double-blinded, placebo-controlled, crossover trial 
(Packer et al., 2016) found reduced scores for stranger-directed fear in dogs receiving a diet 
shown to be ketogenic despite low levels of medium-chain triglycerides, suggesting a positive 
effect on anxiety levels.  A strict, pre-packaged ketogenic diet is easier to enforce in a dog than 
in a child or adult without impacting on QoL and so further research into the anxiolytic, and 
anticonvulsant, effects of ketogenic diets in dogs with ADCE is warranted.  
 
Additionally, alternative therapies have been used to reduce seizure frequency in people 
such as cognitive behavioural therapy and bright light therapy (Brandt and Mula, 2016), 
however, evidence into their use as an anxiolytic is limited.  Cognitive behavioural therapy was 
shown to significantly lower anxiety scores in a small pilot study (Macrodimitris et al., 2011) 
and bright light therapy showed significant difference between treatment and control groups, 
however, the placebo effect could not be accounted for (Baxendale et al., 2013).  Herbal therapy 
such as betony and valerian have been used by people with epilepsy for their anxiolytic 
qualities, however, evidence into their efficacy is poor with no evidence specifically in patients 
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with epilepsy (Pearl et al., 2011).  Owners should take care with complementary therapies as 
there are risks that they interact with AEDs and can have toxic adverse effects.  
 
There is weak evidence of anxiolytic effect of supplements marketed for dogs.  Kato et 
al. (2012) found a significantly smaller rise in urine cortisol to creatinine ratio following nail 
clipping in dogs who were fed a diet supplemented with alpha-casozepine and L-tryptophan 
compared to the same dogs when fed a control diet, whilst Bosch et al. (2009) found no change 
in anxiety-related behaviour in dogs fed a tryptophan supplement compared to controls. 
Palestrini et al, (2010) demonstrated a significant decrease in cortisol levels in anxious dogs 
that received alpha-casozepine as a dietary supplement, though behavioural changes were not 
so clear. Cannas et al. (2013) found a significant decrease in anxiety scores in dogs fed a diet 
containing Valeriana officinalis, Melissa officinalis and tryptophan compared to a control 
group.  Beata et al. (2007) found no statistical difference in anxiety scores and successful 
treatment of dogs receiving alpha-casozepine compared to positive controls receiving 
selegiline hydrochloride.  Dog appeasing pheromone has shown mixed efficacy in controlling 
anxiety (Grigg and Piehler, 2015; Landsberg et al., 2015) and a systematic review found 
insufficient evidence for this product (Frank et al., 2010).  None of these therapies have been 
tested for their anxiolytic effect in dogs with ADCE so direct comparisons cannot be made. 
 
Pharmacokinetic interactions 
Prior to commencement of antidepressants, potential pharmacokinetic drug interactions 
should be noted.  Phenobarbital can increase serum concentrations of antidepressants whilst 
fluoxetine, fluvoxamine and paroxetine can increase serum concentrations of AEDs.  In people 
gabapentin, levetiracetam, pregabalin, topiramate and zonisamide can be used safely in 
conjunction with most antidepressants, whilst citalopram, escitalopram, sertraline, duloxetine, 
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venlafaxine and mirtazapine are considered to have limited interaction with AEDs.  It is worth 
noting to owners who pursue herbal remedies that St. John’s Wort can interfere with AED 
pharmacokinetics causing hepatotoxicity.  For all drug combinations, regular serum 
concentration monitoring should take place (Kondziella and Asztely, 2009).  Pharmacokinetic 
interactions in veterinary behavioural medicine are discussed in detail in Overall (2013). 
 
Behavioural treatment of anxiety in epileptic dogs 
Treatment of anxiety disorders in dogs without epilepsy via behavioural modifications 
can be efficacious with time and repetition, however, the potency of these techniques in an 
epileptic dog with additional neuropathology is unknown.  In order to alter a negative 
emotional response, such as fear or anxiety, to a given stimulus, a veterinary behaviourist 
would use a combination of desensitisation and counterconditioning techniques, but this 
approach will be limited in effectiveness if the animal has a high residual level of emotional 
arousal, which would require preliminary reduction as a first step. Desensitisation involves 
associating the problematic stimulus with a neutral emotional state and involves presentation 
of the stimulus in ways which alters its size or salience, for example by increasing the distance 
at which it is encountered.  Over time, the potential effect of the stimulus can be increased until 
the animal exhibits no behavioural signs of an emotional response when confronted with the 
previously anxiety-inducing stimulus.  Counterconditioning involves associating a positive 
emotional state, through the provision of a positive emotional cue such as food and play, with 
the previously anxiety-inducing stimulus, to avoid the animal redeveloping negative 
associations with the stimulus (Bowen and Heath, 2005).  Instrumental conditioning may also 
have a role to play in behavioural modification for these patients through reinforcing an 
appropriate behavioural response in situations where there is unavoidable exposure to an 
anxiety-inducing stimulus. An example would be the teaching of the use of an appropriate safe 
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refuge to dogs who are anxious or fearful in the presence of loud noises. The aim is to teach 
the dog to use a behavioural response which will minimise its exposure to the stimulus and 
enable it to take some control over its environment. This is preferable to encouraging a dog to 
find refuge with their owner during fearful or anxious times as this can result in a dependence 
on the owner who may not always be present when the stimulus is encountered. Lack of access 
to a learnt coping strategy runs the risk of increasing anxiety but also inducing the emotional 
response of frustration.  When dealing with an anxious or fearful dog punishment should never 
be used as it will usually increase negative emotional motivations (Overall, 1997), which is not 
only counterproductive in terms of establishing positive emotional responses, but also raises 
concerns related to welfare and QoL. 
 
Conclusion 
Anxiety disorders in people with epilepsy is garnering more attention and research, but 
the extent to which it affects dogs is under-investigated and there has been limited veterinary-
specific testing of potential treatments.  Therefore, with the absence of veterinary specific data, 
evidence-based medicine from people with epilepsy must be cautiously and carefully adapted 
and applied.  In ideal circumstances, for veterinary patients with ADCE, an AED with a low 
risk of anxiety should be selected based on human research and reported adverse effects in 
dogs, alongside adequately controlling seizure frequency and severity.  Additionally, a 
behavioural modification plan should be implemented with or without anxiolytic medication 
as described above.  The animal’s emotional state should be assessed and closely monitored in 
newly-diagnosed dogs with epilepsy or throughout initiation of a new AED therapy or 
anxiolytic medication so that acute and chronic changes can be accurately accounted for and 
treatment can be tailored effectively. AED serum levels should be closely monitored when 
incorporating additional medications.  
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 Of course, anxiety disorders are not the only psychological comorbidity to be 
considered; a change in AED or additional medication could improve clinical signs of anxiety 
but cause hyperactivity or decrease attention capability, for example.  Additionally, control of 
a comorbidity will not necessarily improve seizure control and improving seizure control may 
not reduce behavioural comorbidities, so a vet and an owner should work together to find a 
balance for each patient to carefully assess specific features of the disease and how that impacts 
a patient and their family day to day, with the aim of optimising QoL for them all.  Clearly 
further veterinary research is warranted on the effect and treatment of dogs with epilepsy and 
psychological and behavioural comorbidities and it is vital that general practice and neurology 
specialists clinicians work with veterinary behaviour specialists to improve and validate 
diagnostics and treatment of these patients. QoL of an epileptic patient is paramount and we 
would do our companions a great disservice by considering epilepsy as a condition solely 
defined by seizures. 
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Table 1: Summary table of evidence for anxiogenic and anxiolytic 
effects of AED in human and veterinary medicine. 
 
Anti-epileptic 
drug (AED) 
Evidence for 
anxiolytic action 
from human 
medicine 
Evidence for 
anxiogenic action 
from human 
medicine 
Evidence for from 
veterinary medicine 
Phenobarbital  
Use of primidone 
predicted anxiety after 
logistic regression 
analysis in a cross-
sectional study of 196 
patients with epilepsy.  
(Lopez-Gomez et al, 
2008) 
No evidence of 
increased anxiety as 
an adverse effect 
based on a systematic 
review of 43 
monotherapy papers. 
(Charambolous et al, 
2016) 
Potassium 
Bromide 
  
No evidence of 
increased anxiety as 
an adverse effect 
based on a systematic 
review of 8 
monotherapy papers 
and 16 adjunctive 
therapy papers. 
(Charambolous et al, 
2016) 
Levetiracetam 
Levetiracetam could 
be both an efficacious 
AED and anxiolytic. 
(Hagemann et al, 
2013)  
 
A systematic review 
found that patients 
treated with 
levetiracetam had 
lower incidence of 
behavioural problems.  
(Cramer et al, 2003)   
 
No evidence of 
increased anxiety as 
an adverse effect 
based on a systematic 
review of 2 
monotherapy papers 
and 4 adjunctive 
therapy papers. 
(Moore et al, 2010; 
Fredso et al, 2015) 
Pregabalin 
Reduced seizure 
frequency and 
significantly reduced 
anxiety scores in 
epileptic patients 
diagnosed with a 
comorbid anxiety 
disorder. 
(Brandt et al, 2013)  
 
There was not enough 
evidence to assess 
safety profile or 
adverse effects.   
(Charambolous et al, 
2016) 
Gabapentin 
Considered a mood 
enhancer and showed 
 
There was not enough 
evidence to assess 
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no significant 
anxiogenesis between 
control or treated 
adults as an add-on 
AED. 
(Harden et al, 1999) 
safety profile or 
adverse effects.   
(Charambolous et al, 
2016) 
Zonisamide 
Significantly 
decreased anxiety in 
historic non-
responders and in 
newly-diagnosed 
children. 
(Kinrys et al, 2007) 
(Eun et al, 2011) 
A 3% increase in 
anxiety was seen in 
treated patients 
compared to controls 
in a double-blinded 
add-on trial. 
(Cramer et al, 2003) 
No evidence of 
increased anxiety as 
an adverse effect 
based on a systematic 
review of 5 
monotherapy papers.  
Evidence was 
considered weak. 
(Charambolous et al, 
2016) 
Topiramate  
12.9% of epileptic 
patients with add-on 
topiramate developed 
anxiety. 
(Mula and Trimble, 
2003) 
 
Less than 5% reported 
incidence of anxiety in 
429 epileptic patients 
during short- and 
long-term drug 
therapy. 
(Bootsma et al, 2009) 
There was not enough 
evidence to assess 
safety profile or 
adverse effects.  
(Charambolous et al, 
2016)  
Felbamate  
A small, randomized, 
placebo controlled 
study found that six of 
13 patients receiving 
felbamate 
monotherapy dropped 
out due to intolerable 
adverse effects 
including anxiety. 
(Theodore et al, 1995) 
No evidence of 
increased anxiety as a 
adverse effect based 
on a systematic review 
of 3 monotherapy 
papers.  Evidence was 
considered weak. 
(Charambolous et al, 
2016) 
Imepitoin   
No change in fear and 
anxiety-related 
behavioural scores in 
85 dogs before or 
during treatment for 
IE with imepitoin. 
(Packer at al, 2017) 
 
ACVIM consensus 
statement reported no 
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anxiety as an adverse 
effect of imepitoin. 
(Podell et al, 2016) 
 
Anxiety reported as a 
less common, dose-
dependent and 
reversible adverse 
effect in a systematic 
review of 6 
monotherapy and 2 
adjunctive therapy 
papers.   
(Charambolous et al, 
2016) 
Polypharmacy 
No significant 
difference in anxiety 
levels or increased 
adverse effect levels in 
polypharmacy patients 
compared to 
monotherapy human 
patients.   
(Ettinger et al, 1998) 
(Ijff et al (2015) 
Polypharmacy was a 
significant risk factor 
associated with 
increased anxiety 
following regression 
analysis in 35, 102 and 
101 children and 
adolescent patients. 
(Oguz, 2002) 
(Adewuya & Ola, 
2005) 
(Williams et al, 2003) 
No evidence available. 
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